Teva reports year of growth with revenues up 6%

29 January 2025

Israeli generics giant Teva Pharmaceutical Industries (NYSE and TASE: TEVA) today reported results for the year and the quarter ended December 31, 2024.

2024 revenues of $16.5 billion reflect an increase of 6%, in local currency terms, compared to 2023, said Teva, whose shares were down 7.1% at 7,395 shekels following the announcement. as the company's 2025 outlook came in below expectations.

The company expects earnings per share of $2.35-$2.65 this year, below the $2.78 consensus. It projects 2025 revenue of $16.8-17.4 billion, compared to analyst estimates of $17.09 billion.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Generics